FinaBio's Search For A CDMO To Support Affordable Conjugate Vaccines

Fina Biosolutions (FinaBio), a self-funded biotechnology company, is dedicated to increasing the affordability of conjugate vaccines. To achieve this mission, FinaBio sought a contract development and manufacturing organization (CDMO) partner for cGMP production of EcoCRM®, their genetically detoxified diphtheria toxin used as a carrier protein in vaccines.

After evaluating more than 10 CDMOs, Fina Biosolutions (FinaBio) announced Scorpius BioManufacturing as its chosen contract development and manufacturing organization (CDMO) partner for the production of EcoCRM®. Finding a CDMO with flexibility, secure supply chain, and commitment to small biotechs were key reasons behind the selection. Scorpius will be responsible for various aspects of production, including the recovery and downstream process optimization, analytical method implementation and validation, scale-up, and cGMP bulk drug substance manufacturing.

Learn how finding a CDMO that prioritizes custom, flexible partnership over a transactional relationship is crucial for long-term programs and for tailoring services to meet the needs of small-volume clients.